Survival in breast cancer patients after the first episode of hypercalcaemia

Journal of Internal Medicine

Volumn 244, Issue 3, 1998, Pages 189-198

  Kristensen, B ^a,b   Ejlertsen, B ^a   Mouridsen, H T ^a   Loft, H ^a  

^a Mental Health Services CPH   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

Author keywords

Breast cancer; Hypercalcaemia; Survival

Indexed keywords

AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM ION; CLODRONIC ACID; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; HEMOGLOBIN; METHOTREXATE; MITHRAMYCIN; MITOXANTRONE; PAMIDRONIC ACID; PREDNISOLONE; PROGESTERONE RECEPTOR; SODIUM CHLORIDE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER RECURRENCE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REHYDRATION; SURVIVAL TIME;

BREAST NEOPLASMS; CALCIUM; DIPHOSPHONATES; FEMALE; HUMANS; HYPERCALCEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031814482     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00355.x     Document Type: Article

References (22)

1. Kristensen B, Ejlertsen B, Holmegaard SN, Krarup-Hansen A, Transbøl I. Mouridsen H. Prednisolone in the treatment of severe malignant hypercalcaemia in metastatic breast cancer: A randomized study. J Intern Med 1992; 232: 237-45.
2. EORTC Breast Cancer Cooperative Group. Revision of standards for the assessment of hormone receptors in human breast cancer: Report of the Second EORTC Workshop, held on March 16-17, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980; 16: 1513-15.
3. Collett D. Modelling Survival Data in Medical Research. London: Chapman & Hall, 1994.
4. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-10.
5. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61-6.
6. Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ. Hypercalcaemia in patients with disseminated breast cancer. Acta Oncol 1990; 29: 577-80.
7. de Wit S, Cleton FJ. Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 1994; 120: 610-14.
8. Ladenson JH, Lewis JW, Boyd JC. Failure of total calcium corrected for protein, albumin, and pH to correctly assess free calcium status. J Clin Endocrinol Metab 1978; 46: 986-93.
9. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992; 44 (Suppl. 4): 17-28.
10. Andersen B. Methodological Errors in Medical Research. An incomplete catalogue. Oxford: Blackwell Scientific Publications, 1990.
11. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using 'optimal' cutpoints in the evaluation of prognostic factors. J Nat Cancer Inst 1994; 86: 829-35.
12. Rotstein S, Glas U, Eriksson M, Pfeiffer P, Hansen J, Söderqvist J et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - a prospective randomised placebo-controlled multicentre trial. Eur J Cancer 1992; 28A: 890-3.
13. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10: 134-42.
14. Ling PJ, A'Hern RP, Hardy JR. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer 1995; 72: 206-9.
15. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-19.
16. Pecherstorfer M, Schilling T, Blind E, Zimmer-Roth I, Baumgartner G, Ziegler R et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78: 1268-70.
17. Heath H, III, Earll JM, Schaaf M, Piechocki JT, Li T-K. Serum ionized calcium during bed rest in fracture patients and normal men. Metabolism 1972; 21: 633-40.
18. Gallacher SJ, Ralston SH, Dryburgh FJ, Logue FC, Allam BF, Boyce BF et al. Immobilization-related hypercalcaemia - a possible novel mechanism and response to pamidronate. Postgrad Med J 1990; 66: 918-22.
19. Legha SS, Powell K, Buzdar AU, Blumenschein GR. Tamoxifen-induced hypercalcemia in breast cancer. Cancer 1981; 47: 2803-6.
20. Axelrod DM, Bockman RS, Wong GY, Osborne MP, Kinne DW, Brennan MF. Distinguishing features of primary hyperparathyroidism in patients with breast cancer. Cancer 1987; 60: 1620-4.
21. Hutchesson ACJ, Bundred NJ, Ratcliffe WA. Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J 1995; 71: 28-31.
22. Kristensen B, Mouridsen HT, Holmegaard SN, Transbøl I. Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer. Cancer 1989; 64: 1965-7.